November 4, 2025
Revolution Medicines to Participate in November 2025 Investor Conferences
October 29, 2025
Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025
October 27, 2025
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
October 22, 2025
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
October 16, 2025
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program
September 29, 2025
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
September 10, 2025
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
August 6, 2025
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
July 30, 2025
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
July 24, 2025
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor